As monotherapy for the first-line treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
As monotherapy for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and who have received prior systemic therapy.
Indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.
Reimburse with clinical criteria and/or conditions
The requested reimbursement criteria are provided by the applicant and do not
the views of CADTH. Reimbursement criteria from CADTH will be documented in the final
recommendation, if applicable.
Call for patient/clinician input open
Call for patient/clinician input closed
- Patient input submission received from the Canadian Lung Cancer Advocacy Group Breathe Hope, CanCertainty and Lung Cancer Canada
- Submission was not accepted for review on 31 Aug 21
Draft CADTH review report(s) provided to sponsor for comment
Deadline for sponsors comments
CADTH review report(s) and responses to comments provided to sponsor
Expert committee meeting (initial)
Draft recommendation issued to sponsor
Draft recommendation posted for stakeholder feedback
End of feedback period
Final recommendation issued to sponsor and drug plans
Final recommendation posted
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)